Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...
Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...
TAMPA, Fla. — A new study of a cancer treatment called HIPEC, heated intraperitoneal chemotherapy, is showing good results when it comes to treating women with metastatic epithelial ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results